1. Home
  2. SNDX vs PRCH Comparison

SNDX vs PRCH Comparison

Compare SNDX & PRCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$20.70

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Porch Group Inc.

PRCH

Porch Group Inc.

HOLD

Current Price

$11.84

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNDX
PRCH
Founded
2005
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
SNDX
PRCH
Price
$20.70
$11.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
8
Target Price
$38.69
$18.63
AVG Volume (30 Days)
2.1M
2.0M
Earning Date
04-30-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
11.56
90.91
EPS
N/A
N/A
Revenue
$172,352,000.00
$482,414,000.00
Revenue This Year
$107.19
$4.15
Revenue Next Year
$41.88
$17.05
P/E Ratio
N/A
N/A
Revenue Growth
627.84
10.18
52 Week Low
$9.42
$6.36
52 Week High
$25.59
$19.44

Technical Indicators

Market Signals
Indicator
SNDX
PRCH
Relative Strength Index (RSI) 43.79 42.31
Support Level $19.28 $9.08
Resistance Level $22.40 $16.47
Average True Range (ATR) 1.22 0.69
MACD -0.36 -0.44
Stochastic Oscillator 5.35 13.05

Price Performance

Historical Comparison
SNDX
PRCH

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About PRCH Porch Group Inc.

Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.

Share on Social Networks: